Phase 4 N=180 IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population
Abdominal Wall Hernia · Pancreatic Diseases · Bowel Disease
Primary: Postoperative Pain Intensity — 33; 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=29 Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults
Substance Withdrawal Syndrome
Primary: Description of Signs and Symptoms of OIWS in Patients Who Scored Positive for Withdrawal Syndrome (OIWS) According to Diagnostic and Statistical Manual of Mental…
Phase 2 N=25 A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)
Chronic Hepatitis B
Primary: Change in Mean log10 HBV DNA From Baseline (Day 1) to Week 12 or Week 24 on ABI H0731 + SOC ETV as Compared to Placebo + SOC ETV — 7.91; 8.03; -4.45; -3.30 Log10…
Phase 3 N=614 2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
Hypoactive Sexual Desire Disorder
Primary: Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall. — 0.63; 0.21; 1.25; 0.70 score on a scale
Phase 2 N=32 A Phase 2 Study of the Effects of 6R-BH4 in Subjects With Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 27; 18; 20; 15 Participants
N/A N=80 Efficacy of Manual Toothbrushes in Removing Dental Plaque
Dental Plaque · Oral Hygiene
Primary: Change From Pre to Post Brushing in Overall Mean Rustogi Modified Navy Plaque Index (RPI) After a Single Brushing Event at Day 0 — -0.09623; -0.12005; -0.09859; -0.09599…
Phase 2 N=82 Exenatide Once Weekly for Smoking Cessation
Smoking Cessation
Primary: Number of Participants Who Self-Reported Abstinence and Who Were Biochemically Verified as Abstinent Via Expired CO Level of ≤ 5ppm — 19; 11 Participants
N/A N=90 Prevention of Necrotizing Enterocolitis of Premature Newborns Under Less Than 1500 g Using Probiotics
Infectious Diseases
Primary: Number of Patients With (NEC) — 0; 1 participants
Phase 4 N=19 Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Dry Eye Comfort Questionnaire, SANDE — 44.77 scores on a scale
Phase 2 N=114 Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Colon Staining in Preparation for Colonoscopy
Primary: Evaluation of Mucosal Staining Efficacy — 6.8; 2.3; 8.1; 7.0 scores on a scale
Phase 2 N=76 A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
Cystic Fibrosis
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 8; 3; 7; 10 participants
N/A N=42 Efficacy and Safety of Nerivio™ for Acute Treatment of Migraine in People With Chronic Migraine
Chronic Migraine
Primary: Proportion of Participants With Reduction of Migraine Headache at 2 Hours Post Treatment — 19 Participants
Phase 4 N=258 Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
Psoriatic Arthritis
Primary: Percent of Patients Achieving American College of Rheumatology Score of at Least 20% (ACR20) Response Criteria on Secukinumab 300 mg and 150 mg vs. Placebo at Week 16…
Phase 2 N=73 A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
Chronic Hepatitis B
Primary: Change in Mean log10 Serum HBsAg From Baseline (Day 1) to Week 24 on ABI-H0731 + SOC NUC as Compared to Placebo + SOC NUC — 3.48; 3.57; 2.99; 3.35 Log10 International…
Phase 3 N=1,708 Confirmatory Study of 17P vs Vehicle for Prevention of Preterm Birth in Women w/ Previous Spontaneous Preterm Delivery
Preterm Birth
Primary: Preterm Birth <35 Weeks Gestation — 66; 122 Participants